Psychiatr. pro Praxi, 2006; 1: 16-19

SECOND GENERATION ANTIPSYCHOTICS IN RELAPSE PREVENTION OF SCHIZOPHRENIA - THE RECENT FINDINGS FROM SELECTED DOUBLE-BLIND, RANDOMIZED TRIALS

Mudr. Ján Pečeňák CSc
Psychiatrická klinika FN a LF UK Bratislava

Schizophrenia is a disease with a prolonged course and frequently a life time treatment. Second-generation antipsychotics should be undoubtedly advantageous, because of their complex effect and better tolerance. However many factors influencing the treatment complicate the evaluation the effect of individual medications or their classes. A natural unfavorable course of the disease is one of them as well as low compliance with treatment in patients with schizophrenia. These factors are emphasized in the review and results of recently published studies are discussed.

Keywords: Key words: schizophrenia, relapse, second generation antipsychotics.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pečeňák J. SECOND GENERATION ANTIPSYCHOTICS IN RELAPSE PREVENTION OF SCHIZOPHRENIA - THE RECENT FINDINGS FROM SELECTED DOUBLE-BLIND, RANDOMIZED TRIALS. Psychiatr. praxi. 2006;7(1):16-19.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Almond S, Knapp M, Francois C, Toumi M, Brugha T. Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry. 2004; 184: 346-351. Go to original source... Go to PubMed...
    2. Andreasen NC, Carpenter WT Jr, Kane JM, Lasser RA, Marder SR, Weinberger DR. Remission in schizophrenia: proposed criteria and rationale for consensus. Am J Psychiatry. 2005; 162: 441-449. Go to original source... Go to PubMed...
    3. Clinical Study Report CN138003; SYNOPSIS. www.clinicalstudyresults.org/documents/company-study_509_5.pdf. Prístup na stránku 12. 12. 2005.
    4. Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, Leadbetter J, Assuncao S. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study.J Clin Psychiatry. 2005; 66: 1021-1030. Go to original source... Go to PubMed...
    5. Furukawa T. Meta-analyses and megatrials: neither is the infallible, universal standard. Evid. Based Ment. Health, 2004; 7: 34-35. Go to original source... Go to PubMed...
    6. Gilbert PL, Harris MJ, McAdams LA, Jeste DV. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995; 52: 173-188. Go to original source... Go to PubMed...
    7. Häfner H, Heiden W. Course and outcome of schizophrenia. In.: Hirsch S.R. Weinberger D. /Eds./: Schizophrenia. Second Edition. Blackwell Publishing, 2003. p. 101-141. Go to original source...
    8. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, Archibald D, Ingenito G, Marcus R, Pigott T. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol. 2003; 6 : 325-337. Go to original source... Go to PubMed...
    9. Lasser R, Rodriguez S, Turkoz I, Gharabawi G, Simpson G. Optimization Of Long-Acting Risperidone For Maintenance Therapy In Schizophrenia. Výveska. International Congress on Schizophrenia Research, April 2-6, 2005; Savannah, USA.
    10. Leucht S, Barnes TR, Kissling W, Engel RR, Correll C, Kane JM. Relapse prevention in schizophrenia with new-generation antipsychotics: a systematic review and exploratory meta-analysis of randomized, controlled trials. Am J Psychiatry. 2003; 160: 1209-1222. Go to original source... Go to PubMed...
    11. Mallinckrodt CH, Sanger TM, Dube S, DeBrota DJ, Molenberghs G, Carroll RJ, Potter WZ, Tollefson GD. Assessing and interpreting treatment effects in longitudinal clinical trials with missing data. Biol Psychiatry. 2003; 15: 754-760. Go to original source... Go to PubMed...
    12. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK. ClinicalAntipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353: 1209-1223. Go to original source... Go to PubMed...
    13. O'Donovan C. Achieving and Sustaining Remission in Depression and Anxiety Disorders: Introduction. Can J Psychiatry, 49, Suppl 1, 2004: 5S-9S.
    14. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole Study Group. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry. 2003; 64: 1048-1056. Go to original source... Go to PubMed...
    15. Roberts G, Wolfson P. The rediscovery of recovery Advan in Psychiat Treat, 2004; 10: 37-49. Go to original source...
    16. Schooler N, Rabinowitz J, Davidson M, Emsley R, Harvey PD, Kopala L, McGorry PD, Van Hove I, Eerdekens M, Swyzen W, De Smedt G.: Early Psychosis Global Working Group. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. Am J Psychiatry. 2005; 162: 947-953. Go to original source... Go to PubMed...

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.